Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke DOI Creative Commons
Martina Migliavacca, Clara Correa‐Paz,

María Pérez‐Mato

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Aug. 17, 2023

Abstract Background: Intravenous administration of fibrinolytic drugs, such as recombinant tissue plasminogen activator (rtPA) is the standard treatment acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because their short plasma half-lives and risk hemorrhagic transformations. Platelet membrane-based nanocarriers have received increasing attention for ischemic stroke therapies, they natural thrombus-targeting activity, can prolong half-life therapy, reduce side effects. In this study, we gone further in developing platelet-derived (defined cellsomes) to encapsulate protect rtPA from degradation. Following lyophilization characterization, formulation properties, biocompatibility, therapeutic effect, hemorrhages were later investigated a thromboembolic model mice. Results: Cellsomes 200 nm size loaded with generated membrane fragments human platelets. The process did not influence nanocarrier distribution, morphology, colloidal stability conferring particle preservation long-term storage. Encapsulated cellsomes showed be effective free at equal concentration without transformations or altering immune response. Conclusions: This study provides evidence safe use lyophilized biomimetic nanomedicine precise thrombolytic stroke. We successfully addressed one main barriers drug application commercialization, storage nanomedicines, overcoming potential chemical physical instabilities nanomedicines when stored an aqueous buffer.

Language: Английский

Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke DOI Creative Commons
Martina Migliavacca, Clara Correa‐Paz,

María Pérez‐Mato

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Jan. 3, 2024

Intravenous administration of fibrinolytic drugs, such as recombinant tissue plasminogen activator (rtPA) is the standard treatment acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because their short plasma half-lives and risk hemorrhagic transformations. Platelet membrane-based nanocarriers have received increasing attention for ischemic stroke therapies, they natural thrombus-targeting activity, can prolong half-life therapy, reduce side effects. In this study we gone further in developing platelet-derived (defined cellsomes) to encapsulate protect rtPA from degradation. Following lyophilization characterization, formulation properties, biocompatibility, therapeutic effect, hemorrhages were later investigated a thromboembolic model mice.

Language: Английский

Citations

8
Application and Development of Cell Membrane Functionalized Biomimetic Nanoparticles in the Treatment of Acute Ischemic Stroke DOI Open Access
Ying Li,

Chuang Wu,

Rui Yang

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(15), P. 8539 - 8539

Published: Aug. 5, 2024

Ischemic stroke is a serious neurological disease involving multiple complex physiological processes, including vascular obstruction, brain tissue ischemia, impaired energy metabolism, cell death, ion pump function, and inflammatory response. In recent years, there has been significant interest in membrane-functionalized biomimetic nanoparticles as novel therapeutic approach. This review comprehensively explores the mechanisms importance of using these to treat acute ischemic with special emphasis on their potential for actively targeting therapies through membranes. We provide an overview pathophysiology present advances study nanoparticles, emphasizing drug delivery precision-targeted therapy. paper focuses bio-nanoparticles encapsulated bionic membranes target treatment. It highlights mechanism action research progress regarding different types bi-onic such erythrocytes, neutrophils, platelets, exosomes, macrophages, neural stem cells treating while improve tissue's state attenuate damage dysfunction. Through in-depth exploration benefits provided by reducing injury dysfunction, this also provides comprehensive cells' along that ameliorate However, it undeniable are still some challenges limitations terms biocompatibility, safety, practical applications clinical translation.

Language: Английский

Citations

8
Nanoparticles targeting the adenosine pathway for cancer immunotherapy DOI

Kehua Jiang,

Jian Wu, Qing Wang

et al.

Journal of Materials Chemistry B, Journal Year: 2024, Volume and Issue: 12(24), P. 5787 - 5811

Published: Jan. 1, 2024

Outline of this review on adenosine pathway inhibitors for cancer immunotherapy.

Language: Английский

Citations

4
Recent advancements in nanobiomaterials for the management of ischemic diseases DOI
Prashant Pingale,

Krutika Pardeshi,

Madhur Kulkarni

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 389 - 436

Published: Jan. 1, 2025

Language: Английский

Citations

0
Nanomedicine: Pioneering Advances in Neural Disease, Stroke and Spinal Cord Injury Treatment DOI Creative Commons

Borish Loushambam,

Sangeeta Yanglem,

Venkatraman Krishnaswami

et al.

Neuroglia, Journal Year: 2025, Volume and Issue: 6(1), P. 9 - 9

Published: Feb. 21, 2025

Background: Neurological disorders such as Alzheimer’s disease (AD), Parkinson’s (PD), stroke, and spinal cord injury (SCI) are significant global health challenges due to their complex pathology limited therapeutic options. Conventional treatments often fail efficiently cross the blood–brain barrier (BBB), leading poor bioavailability systemic toxicity. This narrative review explores potential of nanomedicine in addressing these limitations advancing targeted therapies for neural disorders. Methods: examines recent studies on use engineered nanoparticles (NPs), including liposomes, dendrimers, micelles, nanogels, drug delivery multifunctional theranostics diseases. It evaluates role promoting axon regeneration, reducing neuroinflammation, repairing damage. Additionally, innovative applications gene therapy RNA-based treatments, CRISPR-Cas9 RNA interference (RNAi), discussed. Challenges related toxicity, scalability, affordability, regulatory barriers highlighted, along with strategies address issues. Results: Nanoparticles have shown promise crossing BBB, delivering agents tissues, minimizing off-target effects. Emerging demonstrate versatility disease-specific challenges. However, unresolved issues long-term safety, manufacturing cost continue pose Conclusions: Nanomedicine offers a promising approach overcoming current treatment emphasizes need continued interdisciplinary efforts translational highlights improve outcomes quality life patients disorders, SCI.

Language: Английский

Citations

0
Nanoparticles Designed Based on the Blood‐Brain Barrier for the Treatment of Cerebral Ischemia‐Reperfusion Injury DOI Open Access

Zhi‐Wei Du,

Yaosheng Li,

Xinchi Jiang

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: March 5, 2025

Cerebral ischemia-reperfusion injury (CI/RI) is currently considered a significant factor affecting the prognosis of ischemic stroke. The blood-brain barrier (BBB) plays multiple roles in treatment ofCI/RI. BBB leakage allows bloodborne toxins to exacerbate stroke pathology. Yet as physiological that separates blood from brain, also poses obstacle therapeutic drug delivery. Therefore, it essential consider both crossing and repairing process CI/RI. Leveraging exceptional benefits nanoparticles (NPs) for penetration targeted repair, numerous NPs are developed promising delivery platforms. Considering complex role CI/RI, this review delves into strategies designing cross BBB, focusing on peptide-modified NPs, cell-mediated cell membrane-derived BBB-modulating NPs. Additionally, summarizes design targeting endothelial cells (ECs), astrocytes, those aimed at regulating microenvironment repair BBB. On basis, reveals prospects challenges designed around CI/RI treatment. And highlights need combine permeability promotion nanoparticle based achieve more effective

Language: Английский

Citations

0
Smart nucleic acid nanodrug delivery system for precision therapeutics DOI
Yu Chen,

Zongkang Guo,

Jing Li

et al.

Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 535, P. 216673 - 216673

Published: April 3, 2025

Language: Английский

Citations

0
Metformin-induced precise targeted inhibition of ischemic neuronal death by a programable endogenous ROS-responsive nanoprodrug DOI
Xiaofeng Tan, Ying Li, Jin Hao

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 162106 - 162106

Published: April 1, 2025

Language: Английский

Citations

0
Nanodrug delivery systems for regulating microglial polarization in ischemic stroke treatment: A review DOI Creative Commons
Shuang-Yin Lei, Yuqian Yang, Jiacheng Liu

et al.

Journal of Tissue Engineering, Journal Year: 2024, Volume and Issue: 15

Published: Jan. 1, 2024

The incidence of ischemic stroke (IS) is rising in tandem with the global aging population. There an urgent need to delve deeper into pathological mechanisms and develop new neuroprotective strategies. In present review, we discuss latest advancements research on various nanodrug delivery systems (NDDSs) for targeting microglial polarization IS treatment. Furthermore, critically different NDDSs have demonstrated exceptional qualities effectively permeate blood–brain barrier, aggregate at site injury, target specific cell types within brain when appropriately modified. Consequently, considerable potential reshaping phenotype microglia could be a prospective therapeutic strategy IS. treatment remains challenge. However, this review provides perspective neuro-nanomedicine therapies centered polarization, thereby inspiring ideas directions.

Language: Английский

Citations

2
Biomimetic astrocyte cell membrane-fused nanovesicles for protecting neurovascular units in hypoxic ischemic encephalopathy DOI Creative Commons
Zihao Liu, Qian Xia,

Chanyue Wang

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Dec. 19, 2024

Hypoxic ischemic encephalopathy (HIE) refers to neonatal hypoxic brain injury caused by severe asphyxia during the perinatal period. With a high incidence rate and poor prognosis, HIE accounts for 2.4% of global disease burden, imposing heavy burden on families society. Current clinical treatment primarily focuses symptomatic management supportive care. Therefore, developments effective strategies new drug formulations are critical improving prognosis patients. In order protect compromised neurovascular units after HIE, we prepared membrane-fused nanovesicles delivering rapamycin si EDN1 (TRCAM@RAPA@si EDN1). Due homotypic targeting feature nanovesicles, employed astrocyte membranes as synthetic materials improve astrocytes in while reducing clearance circulatory system. Additionally, surface cell membrane was modified with CXCR3 receptors, enhancing homing infarcted lesions. Lipid vesicles were TK RVG29 transmembrane peptides, enabling responsive release internal drugs blood-brain barrier penetration. Internally loaded could promote protective autophagy astrocytes, cellular oxidative stress, reduce expression level endothelin gene, thereby secondary damage units.

Language: Английский

Citations

2